IO Frontiers World 2019

Glynn Wilson, Chairman & CEO, TapImmune - Speaker Interview

Glynn discusses their fast-tracked investigative immunotherapy and how they are designing trials to improve clinical translation. 

The trial design for an immuno-oncology therapy can often be as complicated as the science itself! Designing effective clinical trials and translational models is a top priority for anyone in the immuno-oncology industry.

What are your biggest challenges when designing translational studies?

We spoke with Glynn Wilson, CEO and Chairman at TapImmune, earlier this year to discuss just this.
In this video, Glynn discusses:

  • A detailed overview of TapImmune’s fast-track therapy for ovarian cancer for platinum sensitive patients
  • TapImmune’s approach to designing and building translational studies
  • The end goal of preventing metastasing cancers




View More


  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy